Yeni Tanı Almış Metformin Kullanan Tip 2 Diyabetes Mellituslu Hastalarda Serum İrisin Seviyelerinin İncelenmesi

Amaç: İrisin enerji metabolizması yollarının düzenlenmesinde rol alan ve Tip 2 diyabet(T2DM)'li kişilerde kandaki miktarı azalan bir hormondur. Metformin de yakıt ve enerji metabolizmasını etkileyen ve Tip 2 diyabet tedavisinde çok yaygın olarak kullanılan bir ilaçtır. Bu bilgilerden hareketle bu çalışmada, metformin kullanımının serum irisin seviyesi üzerine etkisinin aydınlatılması amaçlanmıştırYöntemler: Endokrinoloji ve Metabolizma Hastalıkları Bilim Dalı' na başvuran ve OGTT sonucu glukoz toleransının bozulmuş olduğu belirlenen 20 kişi çalışmaya dahil edilmiştir. Egzersiz ve beslenme gibi hayat tarzlarında değişiklik ve metformin kullanılması tavsiye edilen bu kişilerden 1 aylık dönemin ardından tekrar kan alınmıştır. Ayrıca, hasta grubuyla yaş ve cinsiyet olarak eşleşen sağlıklı kişilerden oluşan bir kontrol grubu oluşturulmuş (n=20 ), bu iki gruptan alınan kan örneklerindeki irisin seviyeleri ELISA metoduyla ölçülmüştür Bulgular: Hasta grubunun tedavi öncesi kan örneklerindeki irisin seviyeleri ile bir ay boyunca tavsiye edilen tedavileri sonrası alınan kan örneklerindeki irisin seviyeleri arasında önemli bir farklılık olmadığı gözlemlenmiştir (p=0.780). Kontrol grubuyla tedavi gören grup arasında da benzer bir sonuç elde edilirken (p=0.170), kontrol grubuyla hasta grubunun tedavi öncesi örneklerindeki irisin miktarları karşılaştırıldığında, kontrol grubunun serum irisin değerinin anlamlı derecede daha fazla olduğu bulunmuştur (p=0.002). Sonuç:Sonuç olarak, hayat tarzının değiştirilerek alınan metforminin T2DM'li hastaların kanlarındaki irisin seviyesini değiştirip, değiştirmediği konusunda net bir kanaate varılamamıştır.

Investigation of Serum Irisin Levels of Patients with Metformin Taking New Onset Type 2 Diabetes Mellitus

Objective: Irisin has a role in the regulation of energy metabolism pathways and its level in the blood has been shown to decrease in persons with Type 2 Diabetes (T2DM). Metformin which is a frequently used drug in treatment of T2DM, also affects the energy metabolism. In this study, by regarding this relationship, it is aimed to reveal the effect metformin on serum irisin levels. Methods: 20 patients who had applied to Department of Endocrinologic and Metabolic Diseases and whose OGTT had been found to be impaired were included to this investigation. They were recommended to take metformin and to change their life style and their blood were taken after 1 month. Also, a healthy control group (n=20 ) were formed from persons with almost a similar age and sexual distribution as the patient group and the irisin levels of the blood samples taken from these two groups had been measured by ELISA method. Results: Measurements did not show a significant difference (p=0.780) between the irisin levels of the blood samples taken from the patients before and after 1 month recommended treatment. A similar result were found between the control and the treated groups (p=0.170), while a significant increase (p=0.002) were observed for the irisin levels of the control group when compared with the patients group before treatment. Conclusion: The results obtained from this study had not shown clearly if metformin taken together with the life style change by patients with T2DM had changed their blood irisin levels.

PDF

___

1. So B, Kim H, Kim J, et al. Exercise-induced myokines in health and metabolic diseases. IMR. 2014;3:172-9.
2. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. PhysiolRev. 2008;88:1379-406.
3. Steensberg A, Van Hall G, Osada T, et al. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol. 2000;529:237-42.
4. Henningsen J, Rigbolt KT, Blagoev B, et al. Dynamics of the skeletal muscle secretome during myoblast differentiation. Mol Cell Proteomics. 2010;9:2482-96.
5. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-? dependent myokine that drives browing of White fat and thermogenesis. Nature. 2012; 481: 463-468.
6. Erickson HP. Irisinand FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte. 2013;2:289-93.
7. Vijan S. Intheclinic. Type 2 diabetes. Ann Int Med. 2010;152:3-1.
8. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med. 2004;116:23-9.
9. Standl E, Füchtenbusch M. The role of oral antidiabetic agents: why and whentouse an early-phase insülin secretion egent in Type II diabetes mellitus. Diabetologia. 2003; 46: 30-6.
10. Scarpello J, Howlett H. Metformin therapy and clinical uses. DiabetesVascDisRes. 2008; 5: 157-67.
11. Hundal RS, Krssak M, Dufour S. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000; 49: 2063-9.
12. Guilherme A, Virbasius JV, Puri V, et al. Adipocyte dysfunctions linking obesity to insülin resistance and type 2 diabetes. NatRevMol Cell Biol. 2008;9:367-77.
13. Yan J, Feng Z, Liu J, et al. Enhanced autophagy plays a cardinal role in mitochondrial dysfunction in type 2diabetic Goto-Kakizaki (GK) rats: ameliorating effects of (-)- epigallocatechin-3-gallate. J NutrBiochem. 2012;23:716-24.
14. Grisouarda J, Timpera K, Radimerskia TM, et al. Mechanisms of metforminaction on glucose transport and metabolism in human adipocytes. Biochem Pharmacol. 2010;80:1736-45.
15. Choi YK, Kim MK, Bae KH, et al. Serum irisin levels in new-onsettype 2 diabetes. DiabetesResClinPract. 2013;100:96-1.
16. Xiang L, Xiang G, Yue L, et al. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis. 2014; 235:328-33.
17. Kurdiova T, Balaz M, Vician M, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitrostudies. J Physiol. 2014; 592: 1091-107.
18. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoSOne. 2014 9:94-235.
19. Espes D, Lau J, Carlsson PO. Increased levels of irisin in people with long-standing Type 1 diabetes. Diabet Med. 2015; 32:1172-6.
20. Li DJ, Huang F, Lu WJ, et al. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. ActaPhysiol. 2014; 213:711-21.
21. Varela-Rodríguez BM, Pena-Bello L, Juiz-Valiña P, et al. FNDC5 expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle. SciRep. 2016; 19:6-29898.
22. Li M, Yang M, Zhou X, et al. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015:100:1485-93.